MA41287A - Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement - Google Patents
Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellementInfo
- Publication number
- MA41287A MA41287A MA041287A MA41287A MA41287A MA 41287 A MA41287 A MA 41287A MA 041287 A MA041287 A MA 041287A MA 41287 A MA41287 A MA 41287A MA 41287 A MA41287 A MA 41287A
- Authority
- MA
- Morocco
- Prior art keywords
- restricted
- hla molecules
- against cancer
- absolute quantification
- process allowing
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56977—HLA or MHC typing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70539—MHC-molecules, e.g. HLA-molecules
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2496/00—Reference solutions for assays of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Zoology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Abstract
La présente invention se rapporte à un procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement, à savoir la détermination du nombre de copies d'un ou de plusieurs peptides tel que présenté par cellule. La présente invention peut non seulement être utilisée pour le développement des traitements par anticorps ou des vaccins peptidiques mais est également très précieuse pour une immunosurveillance dont la composition moléculaire a été définie, et utile dans les procédés d'identification de nouveaux antigènes peptidiques pour des stratégies immunothérapeutiques, telles que des vaccins respectifs, des thérapies à base d'anticorps ou des approches de transfert adoptif de lymphocytes t dans la lutte contre le cancer et/ou les maladies auto-immunes.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462097994P | 2014-12-30 | 2014-12-30 | |
| GBGB1423361.3A GB201423361D0 (en) | 2014-12-30 | 2014-12-30 | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| PCT/EP2015/079873 WO2016107740A1 (fr) | 2014-12-30 | 2015-12-15 | Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA41287A true MA41287A (fr) | 2017-11-08 |
| MA41287B1 MA41287B1 (fr) | 2021-07-29 |
Family
ID=52471641
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40137A MA40137B1 (fr) | 2014-12-30 | 2015-12-15 | Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement |
| MA41287A MA41287B1 (fr) | 2014-12-30 | 2015-12-15 | Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40137A MA40137B1 (fr) | 2014-12-30 | 2015-12-15 | Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US10545154B2 (fr) |
| EP (1) | EP3241026B1 (fr) |
| JP (1) | JP6735741B2 (fr) |
| KR (1) | KR102336968B1 (fr) |
| CN (1) | CN107003322B (fr) |
| AU (1) | AU2015373584B2 (fr) |
| BR (1) | BR112017008212B1 (fr) |
| CA (1) | CA2972306C (fr) |
| CL (1) | CL2017001071A1 (fr) |
| CO (1) | CO2017004543A2 (fr) |
| CR (1) | CR20170297A (fr) |
| CY (1) | CY1124223T1 (fr) |
| DK (1) | DK3241026T3 (fr) |
| EA (1) | EA036328B1 (fr) |
| ES (1) | ES2871035T3 (fr) |
| GB (1) | GB201423361D0 (fr) |
| HR (1) | HRP20210811T1 (fr) |
| HU (1) | HUE054455T2 (fr) |
| IL (1) | IL250982B (fr) |
| LT (1) | LT3241026T (fr) |
| MA (2) | MA40137B1 (fr) |
| MD (1) | MD3241026T2 (fr) |
| MX (1) | MX2017008722A (fr) |
| MY (1) | MY190199A (fr) |
| PE (1) | PE20171136A1 (fr) |
| PH (1) | PH12017500483A1 (fr) |
| PL (1) | PL3241026T3 (fr) |
| PT (1) | PT3241026T (fr) |
| RS (1) | RS61914B1 (fr) |
| SG (2) | SG11201703841VA (fr) |
| SI (1) | SI3241026T1 (fr) |
| TW (1) | TWI632370B (fr) |
| UA (1) | UA122774C2 (fr) |
| WO (1) | WO2016107740A1 (fr) |
| ZA (1) | ZA201701646B (fr) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| CR20210232A (es) * | 2015-03-17 | 2022-06-24 | Immatics Biotechnologies Gmbh | NUEVOS PÉPTIDOS Y NUEVA COMBINACIÓN DE PÉPTIDOS PARA EL USO EN LA INMUNOTERAPIA CONTRA EL CÁNCER DE PÁNCREAS Y OTROS TIPOS DE CÁNCER (Divisional 2017-0419) |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| EP4317432A3 (fr) | 2016-12-08 | 2024-04-17 | Immatics Biotechnologies GmbH | Récepteurs de lymphocytes t à appariement amélioré |
| SG11202000027WA (en) | 2017-07-14 | 2020-02-27 | Immatics Biotechnologies Gmbh | Improved dual specificity polypeptide molecule |
| DE102017127984B4 (de) | 2017-11-27 | 2019-12-05 | Immatics US, Inc. | Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen |
| CN111684062A (zh) | 2018-02-09 | 2020-09-18 | 伊玛提克斯美国公司 | 制造t细胞的方法 |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| KR20200027858A (ko) * | 2018-09-05 | 2020-03-13 | 에스케이하이닉스 주식회사 | 메모리 컨트롤러 및 이를 포함하는 메모리 시스템 |
| TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| US20200297768A1 (en) | 2019-03-19 | 2020-09-24 | Immatics US, Inc. | Cd28 t cell cultures, compositions, and methods of using thereof |
| EA202193139A1 (ru) | 2019-05-27 | 2022-03-01 | Имматикс Юс, Инк. | Вирусные векторы и их применение в адоптивной клеточной терапии |
| KR20220018006A (ko) | 2019-06-06 | 2022-02-14 | 이매틱스 바이오테크놀로지스 게엠베하 | 서열 유사 펩티드를 사용하는 계수기 선택에 의한 분류 |
| US20210032370A1 (en) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Recruiting agent further binding an mhc molecule |
| DE102019121007A1 (de) | 2019-08-02 | 2021-02-04 | Immatics Biotechnologies Gmbh | Antigenbindende Proteine, die spezifisch an MAGE-A binden |
| EP4010708A1 (fr) | 2019-08-09 | 2022-06-15 | Immatics US, Inc. | Procédés de prédiction de fragmentation par spectrométrie de masse de peptides |
| US20210048442A1 (en) | 2019-08-13 | 2021-02-18 | Immatics Biotechnologies Gmbh | Method for the characterization of peptide:mhc binding polypeptides |
| IL295891A (en) | 2020-02-24 | 2022-10-01 | Immatics Us Inc | Methods for propagating t cells for the treatment of cancer and related malignancies |
| DE102020111571A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| DE102020106710A1 (de) | 2020-03-11 | 2021-09-16 | Immatics US, Inc. | Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren |
| AU2021275049A1 (en) | 2020-05-19 | 2022-12-22 | Amgen Inc. | MAGEB2 binding constructs |
| WO2022040631A1 (fr) | 2020-08-21 | 2022-02-24 | Immatics US, Inc. | Procédés d'isolement de lymphocytes t sélectionnés cd8+ |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| JP2024502034A (ja) | 2020-12-31 | 2024-01-17 | イマティクス ユーエス，アイエヌシー． | Ｃｄ８ポリペプチド、組成物、及びそれらの使用方法 |
| BR112023022975A2 (pt) | 2021-05-05 | 2024-01-23 | Immatics Biotechnologies Gmbh | Polipeptídeos de ligação ao antígeno bma031 melhorados |
| TW202309071A (zh) | 2021-05-05 | 2023-03-01 | 德商英麥提克生物技術股份有限公司 | 特異性結合ｐｒａｍｅ之抗原結合蛋白 |
| US20230024554A1 (en) | 2021-06-28 | 2023-01-26 | Immatics Biotechnologies Gmbh | Method of characterizing the binding characteristics between a peptide of interest and mhc molecules |
| EP4113120A1 (fr) | 2021-06-28 | 2023-01-04 | Immatics Biotechnologies GmbH | Procédé de caractérisation des caractéristiques de liaison entre un peptide d'intérêt et des molécules du cmh |
| KR20240038028A (ko) | 2021-07-27 | 2024-03-22 | 이매틱스 바이오테크놀로지스 게엠베하 | Ct45에 특이적으로 결합하는 항원 결합 단백질 |
| WO2023025851A1 (fr) | 2021-08-24 | 2023-03-02 | Immatics US, Inc. | Sélection de cellules immunitaires à l'aide de complexes peptide-cmh générés par échange de ligands conditionnel |
| TW202332765A (zh) | 2021-09-20 | 2023-08-16 | 美商英麥提克斯股份有限公司 | 用於ｔ細胞療法之ｔ細胞群體的單核球耗盡 |
| US20230190807A1 (en) | 2021-10-06 | 2023-06-22 | Immatics Biotechnologies Gmbh | Tcr compounds, compositions, and methods of treating |
| WO2023081925A1 (fr) | 2021-11-08 | 2023-05-11 | Immatics Biotechnologies Gmbh | Traitement combiné de thérapie cellulaire adoptive et compositions associées |
| US20240066127A1 (en) | 2022-04-28 | 2024-02-29 | Immatics US, Inc. | Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof |
| US20230348561A1 (en) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof |
| WO2023212697A1 (fr) | 2022-04-28 | 2023-11-02 | Immatics US, Inc. | Il-15 liée à une membrane, polypeptides de cd8, cellules, compositions et leurs procédés d'utilisation |
| WO2023215825A1 (fr) | 2022-05-05 | 2023-11-09 | Immatics US, Inc. | Procédés d'amélioration de l'efficacité d'un lymphocyte t |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60223696T2 (de) | 2001-09-14 | 2009-01-29 | Electrophoretics Ltd., Cobham | Massenmarker |
| US20050221350A1 (en) * | 2002-05-29 | 2005-10-06 | Toni Weinschenk | Method for identifying immunoreactive peptides |
| DE10225139A1 (de) | 2002-05-29 | 2004-02-26 | Immatics Biotechnologies Gmbh | Verfahren zur Identifizierung von immunreaktiven Peptiden |
| US6644103B1 (en) | 2002-10-24 | 2003-11-11 | Simmonds Precision Products, Inc. | Method and apparatus for detecting a dry/wet state of a thermistor bead |
| AU2003277610A1 (en) * | 2002-11-08 | 2004-06-07 | Shuichi Hanada | Method of examining cancer cells and reagent therefor |
| US7811828B2 (en) | 2004-01-28 | 2010-10-12 | Immatics Biotechnologies Gmbh | Method for identifying and quantifying of tumuor-associated |
| JP2008043332A (ja) * | 2006-08-17 | 2008-02-28 | Panomics Inc | 組織スライドからの核酸定量 |
| DK2172211T3 (en) * | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201006360D0 (en) * | 2010-04-16 | 2010-06-02 | Immatics Biotechnologies Gmbh | Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development |
| WO2012140429A2 (fr) | 2011-04-15 | 2012-10-18 | Micromass Uk Limited | Procédé et appareil pour l'analyse d'échantillons biologiques |
| US9869684B2 (en) | 2011-06-24 | 2018-01-16 | Definitek, Inc. | Accurate measurement of glutathione for disease diagnosis and drug metabolite screening |
| US10077171B2 (en) * | 2012-10-17 | 2018-09-18 | Grant C. Chustz | Safety barrier for vehicles and cranes |
| GB201423361D0 (en) * | 2014-12-30 | 2015-02-11 | Immatics Biotechnologies Gmbh | Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides |
| DE102016115246C5 (de) * | 2016-08-17 | 2018-12-20 | Immatics Biotechnologies Gmbh | Neue t-zellrezeptoren und deren verwendung in immuntherapie |
| DK3707159T3 (da) * | 2017-11-06 | 2023-04-11 | Immatics Biotechnologies Gmbh | Hidtil ukendte modificerede t-cellereceptorer og immunterapi med anvendelse deraf |
-
2014
- 2014-12-30 GB GBGB1423361.3A patent/GB201423361D0/en not_active Ceased
-
2015
- 2015-12-15 MA MA40137A patent/MA40137B1/fr unknown
- 2015-12-15 TW TW104142137A patent/TWI632370B/zh active
- 2015-12-15 CR CR20170297A patent/CR20170297A/es unknown
- 2015-12-15 MX MX2017008722A patent/MX2017008722A/es unknown
- 2015-12-15 PL PL15822924T patent/PL3241026T3/pl unknown
- 2015-12-15 US US14/969,423 patent/US10545154B2/en active Active
- 2015-12-15 ES ES15822924T patent/ES2871035T3/es active Active
- 2015-12-15 WO PCT/EP2015/079873 patent/WO2016107740A1/fr active Application Filing
- 2015-12-15 DK DK15822924.5T patent/DK3241026T3/da active
- 2015-12-15 RS RS20210672A patent/RS61914B1/sr unknown
- 2015-12-15 MY MYPI2017700825A patent/MY190199A/en unknown
- 2015-12-15 SG SG11201703841VA patent/SG11201703841VA/en unknown
- 2015-12-15 SI SI201531612T patent/SI3241026T1/sl unknown
- 2015-12-15 AU AU2015373584A patent/AU2015373584B2/en active Active
- 2015-12-15 EA EA201791148A patent/EA036328B1/ru unknown
- 2015-12-15 BR BR112017008212-8A patent/BR112017008212B1/pt active IP Right Grant
- 2015-12-15 CN CN201580063711.6A patent/CN107003322B/zh active Active
- 2015-12-15 SG SG10201913988XA patent/SG10201913988XA/en unknown
- 2015-12-15 HU HUE15822924A patent/HUE054455T2/hu unknown
- 2015-12-15 KR KR1020177017911A patent/KR102336968B1/ko active IP Right Grant
- 2015-12-15 JP JP2017521534A patent/JP6735741B2/ja active Active
- 2015-12-15 PE PE2017000941A patent/PE20171136A1/es unknown
- 2015-12-15 EP EP15822924.5A patent/EP3241026B1/fr active Active
- 2015-12-15 PT PT158229245T patent/PT3241026T/pt unknown
- 2015-12-15 UA UAA201701977A patent/UA122774C2/uk unknown
- 2015-12-15 LT LTEP15822924.5T patent/LT3241026T/lt unknown
- 2015-12-15 CA CA2972306A patent/CA2972306C/fr active Active
- 2015-12-15 MA MA41287A patent/MA41287B1/fr unknown
- 2015-12-15 MD MDE20170252T patent/MD3241026T2/ro unknown
-
2017
- 2017-03-07 ZA ZA2017/01646A patent/ZA201701646B/en unknown
- 2017-03-07 IL IL250982A patent/IL250982B/en active IP Right Grant
- 2017-03-14 PH PH12017500483A patent/PH12017500483A1/en unknown
- 2017-04-28 CL CL2017001071A patent/CL2017001071A1/es unknown
- 2017-05-05 CO CONC2017/0004543A patent/CO2017004543A2/es unknown
-
2019
- 2019-11-15 US US16/685,765 patent/US11988669B2/en active Active
-
2021
- 2021-05-19 HR HRP20210811TT patent/HRP20210811T1/hr unknown
- 2021-06-10 CY CY20211100514T patent/CY1124223T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA41287A (fr) | Procédé permettant la quantification absolue des peptides contre le cancer restreints aux molécules hla traités naturellement | |
| Abelin et al. | Defining HLA-II ligand processing and binding rules with mass spectrometry enhances cancer epitope prediction | |
| Huang et al. | Ginseng polysaccharides alter the gut microbiota and kynurenine/tryptophan ratio, potentiating the antitumour effect of antiprogrammed cell death 1/programmed cell death ligand 1 (anti-PD-1/PD-L1) immunotherapy | |
| Grimaldi et al. | Combination of chemotherapy and PD-1 blockade induces T cell responses to tumor non-mutated neoantigens | |
| Berlin et al. | Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy | |
| Matos Baltazar et al. | Antibody binding alters the characteristics and contents of extracellular vesicles released by Histoplasma capsulatum | |
| Naghavian et al. | Microbial peptides activate tumour-infiltrating lymphocytes in glioblastoma | |
| JP2013530943A5 (fr) | ||
| Vauchy et al. | CD20 alternative splicing isoform generates immunogenic CD 4 helper T epitopes | |
| Durgeau et al. | Human preprocalcitonin self-antigen generates TAP-dependent and-independent epitopes triggering optimised T-cell responses toward immune-escaped tumours | |
| MA40929A (fr) | Procédé de production d'anticorps à affinité élevée | |
| Nelde et al. | Immunopeptidomics-guided warehouse design for peptide-based immunotherapy in chronic lymphocytic leukemia | |
| MA43794B1 (fr) | Procédés de prédiction de l'utilité de néoantigènes pour l'immunothérapie | |
| Sum et al. | The tumor-targeted CD40 agonist CEA-CD40 promotes T cell priming via a dual mode of action by increasing antigen delivery to dendritic cells and enhancing their activation | |
| Bauer et al. | The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma | |
| Jiang et al. | MYC inhibition reprograms tumor immune microenvironment by recruiting T lymphocytes and activating the CD40/CD40L system in osteosarcoma | |
| Thuring et al. | HLA class I is most tightly linked to levels of tapasin compared with other antigen-processing proteins in glioblastoma | |
| Tomás-Cortázar et al. | The immunosuppressive effect of the tick protein, Salp15, is long-lasting and persists in a murine model of hematopoietic transplant | |
| Kissick et al. | Immunization with a peptide containing MHC class I and II epitopes derived from the tumor antigen SIM2 induces an effective CD4 and CD8 T-cell response | |
| Rose et al. | Therapeutic anti-glioma effect of the combined action of PCSK inhibitor with the anti-tumoral factors secreted by Poly (I: C)-stimulated macrophages | |
| Vormehr et al. | Personalized neo-epitope vaccines for cancer treatment | |
| Yarmishyn et al. | Genome-wide analysis of mRNAs associated with mouse peroxisomes | |
| Han et al. | Streamlined selection of cancer antigens for vaccine development through integrative multi-omics and high-content cell imaging | |
| Calzada-Fraile et al. | Immune synapse formation promotes lipid peroxidation and MHC-I upregulation in licensed dendritic cells for efficient priming of CD8+ T cells | |
| MX369413B (es) | Peptido. |